文献速递糖尿病肥胖与代谢综合征

2型糖尿病患者代餐的疗效与安全性

Efficacy and Safety of Meal Replacement in Patients With Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

本项Meta分析纳入17项随机对照试验共2112例2型糖尿病患者,比较代餐与常规糖尿病饮食的效果。与常规饮食相比,代餐显著降低糖化血红蛋白(MD -0.46%;P < .001)、空腹血糖(-0.62 mmol/L;P < .001)、体重(-2.43 kg;P < .001)和体重指数(-0.65;P < .001),并改善其他心血管代谢危险因素。完全代餐较部分代餐在糖化血红蛋白、空腹血糖、体重和体重指数方面改善更明显,两者耐受性均良好。

要点

  • 与常规糖尿病饮食相比,代餐显著降低2型糖尿病患者的糖化血红蛋白、空腹血糖、体重和体重指数。
  • 完全代餐在糖化血红蛋白、空腹血糖、体重和体重指数方面的改善优于部分代餐。
  • 代餐在胰岛素治疗与非胰岛素治疗患者中获益相似,部分代餐和完全代餐均耐受良好。

核心结论

  • 与常规糖尿病饮食相比,代餐饮食模式进一步改善2型糖尿病患者的血糖控制和脂肪相关指标。
  • 适当的限能量和完全代餐可能更有益,接受胰岛素治疗与未接受胰岛素治疗的患者均可从代餐中相似获益。

研究设计与样本

  • Meta分析,检索PubMed、CENTRAL、Embase、Web of Science和临床试验注册数据库至2022年3月。
  • 纳入17项随机对照试验,共2112例2型糖尿病患者,干预时长2周及以上,比较代餐与常规糖尿病饮食。

主要发现

  • 与常规糖尿病饮食相比,代餐显著降低糖化血红蛋白(MD -0.46%;P < .001)、空腹血糖(-0.62 mmol/L;P < .001)、体重(-2.43 kg;P < .001)和体重指数(-0.65;P < .001),并改善其他心血管代谢危险因素。
  • 亚组分析中,完全代餐较部分代餐在糖化血红蛋白(-0.72% vs -0.32%;P = .01)、空腹血糖(-1.45 vs -0.56 mmol/L;P = .02)、体重(-6.57 vs -1.58 kg;P < .001)和体重指数(-2.78 vs -0.37;P < .001)方面改善更明显。
  • 与不限能量代餐相比,限能量代餐在体重(-3.20 vs -0.75 kg;P < .001)和体重指数(-0.84 vs -0.24;P = .003)方面降低更明显。
  • 在纳入胰岛素治疗患者与未纳入胰岛素治疗患者的研究中,代餐显示出相似的获益。
  • 部分代餐和完全代餐均耐受良好。

临床怎么用

  • 与常规糖尿病饮食相比,代餐饮食模式可进一步改善2型糖尿病患者的血糖控制和脂肪相关指标。
  • 适当的限能量和完全代餐可能更有益,接受胰岛素治疗与未接受胰岛素治疗的患者均可相似地从代餐中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Meal replacement (MR) is beneficial for the management of type 2 diabetes (T2D). However, MR prescription and patient characteristics vary substantially between studies using MR in T2D patients. OBJECTIVE: This work aimed to evaluate the efficacy and safety of MR in T2D patients by meta-analysis, with a focus on subgroup analysis of variable participant characteristics and MR prescription. METHODS: We searched PubMed, CENTRAL, Embase, Web of Science, and the clinical trial registration database up to March 2022. We included randomized controlled trials (RCTs) of 2 weeks or more assessing the effect and safety of MR in T2D patients in comparison with conventional diabetic diets (CDs). RESULTS: A total of 17 RCTs involving 2112 participants were ultimately included. Compared with CDs, MR significantly reduced glycated hemoglobin A1c (HbA1c) (MD -0.46%; P < .001), fasting blood glucose (FBG, -0.62 mmol/L; P < .001), body weight (-2.43 kg; P < .001), and body mass index (BMI, -0.65; P < .001), and improved other cardiometabolic risk factors. In subgroup analyses, total MR showed greater improvement in HbA1c (-0.72% vs -0.32%; P = .01), FBG (-1.45 vs -0.56 mmol/L; P = .02), body weight (-6.57 vs -1.58 kg; P < .001), and BMI (-2.78 vs -0.37; P < .001) than partial MR. MR with caloric restriction showed more reduction in body weight (-3.20 vs -0.75 kg; P < .001) and BMI (-0.84 vs -0.24; P = .003) compared with those without caloric restriction. MR showed similar benefits in studies that included patients using insulin and those that did not. Both partial and total MR were well tolerated. CONCLUSION: Compared with CDs, the MR-based dietary pattern further improved the glycemic control and adipose indicators in T2D patients. Appropriate calorie restriction and total MR might be more beneficial, while both patients treated with or without insulin treatment could similarly benefit from MR usage.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ye W, Xu L, Ye Y, et al. Efficacy and Safety of Meal Replacement in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2023. PMID: 37192345. doi:10.1210/clinem/dgad273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。